PTC Therapeutics, Inc. P/Operating CF

P/Operating CF of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current P/Operating CF of PTC Therapeutics, Inc. is -65.32 (as of December 30, 2020)
  • P/Operating CF for the quarter ending June 29, 2021 was -95.57 (a 188.01% increase compared to previous quarter)
  • Year-over-year quarterly P/Operating CF decreased by -180.57%
  • Annual P/Operating CF for 2020 was -65.32 (a -76.42% decrease from previous year)
  • Annual P/Operating CF for 2019 was -277.01 (a 162.42% increase from previous year)
  • Annual P/Operating CF for 2018 was -105.56 (a -428.47% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of PTC Therapeutics, Inc.

Most recent P/Operating CFof PTCT including historical data for past 10 years.

Interactive Chart of P/Operating CF of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. P/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -95.57 -33.18
2020 -65.32 118.62 -44.19 -34.13 -65.32
2019 -277.01 -123.18 -82.75 -50.11 -277.01
2018 -105.56 662.41 521359.4 -68.08 -105.56
2017 32.14 -54.71 54.52 -11.68 32.14
2016 -28.7 -19.84 -9.71 -5.25 -28.7
2015 -35.92 -32.61 -54.23 -55.24 -35.92
2014 -204.45 -75.83 -40.77 -47.64 -204.45
2013 -15.05 -98.67 -2.04 -0.01 -15.05
2012 -0.01 -0.01 -0.01 -0.01 -0.01
2011 -0.01

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.